ATARA BIOTHERAPEUTICS, INC. Increase (Decrease) in Accounts Receivable
ATARA BIOTHERAPEUTICS, INC. (ATRA) reported Increase (Decrease) in Accounts Receivable of -$935.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsReceivable · last filed 2026-08-12
- ATARA BIOTHERAPEUTICS, INC. increase (decrease) in accounts receivable for the quarter ending 2026-06-30 was $318.00K.
- ATARA BIOTHERAPEUTICS, INC. increase (decrease) in accounts receivable for the quarter ending 2026-03-31 was -$1.25M, a 116.95% decline year-over-year.
- ATARA BIOTHERAPEUTICS, INC. increase (decrease) in accounts receivable for the quarter ending 2025-12-31 was -$660.00K, a 548.98% decline year-over-year.
- ATARA BIOTHERAPEUTICS, INC. increase (decrease) in accounts receivable for the quarter ending 2025-09-30 was $1.91M.
- ATARA BIOTHERAPEUTICS, INC. increase (decrease) in accounts receivable for fiscal 2025 was -$229.00K.
- ATARA BIOTHERAPEUTICS, INC. increase (decrease) in accounts receivable for fiscal 2024 was -$32.63M.
- ATARA BIOTHERAPEUTICS, INC. increase (decrease) in accounts receivable for fiscal 2023 was -$6.11M, a 115.58% decline from fiscal 2022.
- ATARA BIOTHERAPEUTICS, INC. increase (decrease) in accounts receivable for fiscal 2022 was $39.23M.
| Period end | Increase (Decrease) in Accounts Receivable 3 month | Increase (Decrease) in Accounts Receivable 6 month | Increase (Decrease) in Accounts Receivable 9 month | Increase (Decrease) in Accounts Receivable 12 month |
|---|---|---|---|---|
| 2026-06-30 | $318.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | -$935.00K 10-Q · filed 2026-08-12 | -$1.59M derived: sum of 3 quarters · filed 2026-08-12 | $318.00K derived: sum of 4 quarters · filed 2026-08-12 |
| 2026-03-31 | -$1.25M 10-Q · filed 2026-05-12 | -$1.91M derived: sum of 2 quarters · filed 2026-05-12 | $0.00 derived: sum of 3 quarters · filed 2026-05-12 | -$8.88M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-12-31 | -$660.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | $1.25M derived: sum of 2 quarters · filed 2026-03-16 | -$7.62M derived: sum of 3 quarters · filed 2026-08-12 | -$229.00K 10-K · filed 2026-03-16 |
| 2025-09-30 | $1.91M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | -$6.96M derived: sum of 2 quarters · filed 2026-08-12 | $431.00K 10-Q · filed 2025-11-12 | $578.00K derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-06-30 | -$8.88M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | -$1.48M 10-Q · filed 2026-08-12 | -$1.33M derived: sum of 3 quarters · filed 2026-08-12 | -$2.42M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-03-31 | $7.39M 10-Q · filed 2026-05-12 | $7.54M derived: sum of 2 quarters · filed 2026-05-12 | $6.45M derived: sum of 3 quarters · filed 2026-05-12 | -$26.96M derived: sum of 4 quarters · filed 2026-05-12 |
| 2024-12-31 | $147.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | -$940.00K derived: sum of 2 quarters · filed 2026-03-16 | -$34.35M derived: sum of 3 quarters · filed 2026-03-16 | -$32.63M 10-K · filed 2026-03-16 |
| 2024-09-30 | -$1.09M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | -$34.50M derived: sum of 2 quarters · filed 2025-11-12 | -$32.77M 10-Q · filed 2025-11-12 | $1.17M derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | -$33.41M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-11 | -$31.69M 10-Q · filed 2025-08-11 | $2.26M derived: sum of 3 quarters · filed 2025-08-11 | $1.92M derived: sum of 4 quarters · filed 2025-08-11 |
| 2024-03-31 | $1.73M 10-Q · filed 2025-05-15 | $35.67M derived: sum of 2 quarters · filed 2025-05-15 | $35.33M derived: sum of 3 quarters · filed 2025-05-15 | $35.44M derived: sum of 4 quarters · filed 2025-05-15 |
| 2023-12-31 | $33.95M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-07 | $33.60M derived: sum of 2 quarters · filed 2025-03-07 | $33.71M derived: sum of 3 quarters · filed 2025-03-07 | -$6.11M 10-K · filed 2025-03-07 |
| 2023-09-30 | -$344.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | -$234.00K derived: sum of 2 quarters · filed 2024-11-12 | -$40.06M 10-Q · filed 2024-11-12 | -$86.00K derived: sum of 4 quarters · filed 2024-11-12 |
| 2023-06-30 | $110.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-12 | -$39.71M 10-Q · filed 2024-08-12 | $258.00K derived: sum of 3 quarters · filed 2024-08-12 | -$130.00K derived: sum of 4 quarters · filed 2024-08-12 |
| 2023-03-31 | -$39.82M 10-Q · filed 2024-05-09 | $148.00K derived: sum of 2 quarters · filed 2024-05-09 | -$240.00K derived: sum of 3 quarters · filed 2024-05-09 | -$271.00K derived: sum of 4 quarters · filed 2024-05-09 |
| 2022-12-31 | $39.97M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-28 | $39.58M derived: sum of 2 quarters · filed 2024-03-28 | $39.55M derived: sum of 3 quarters · filed 2024-03-28 | $39.23M 10-K · filed 2024-03-28 |
| 2022-09-30 | -$388.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-01 | -$419.00K derived: sum of 2 quarters · filed 2023-11-01 | -$737.00K 10-Q · filed 2023-11-01 | $249.00K derived: sum of 4 quarters · filed 2023-11-01 |
| 2022-06-30 | -$31.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | -$349.00K 10-Q · filed 2023-08-08 | $637.00K derived: sum of 3 quarters · filed 2023-08-08 | $637.00K derived: sum of 4 quarters · filed 2023-08-08 |
| 2022-03-31 | -$318.00K 10-Q · filed 2023-05-08 | $668.00K derived: sum of 2 quarters · filed 2023-05-08 | $668.00K derived: sum of 3 quarters · filed 2023-05-08 | -$8.94M derived: sum of 4 quarters · filed 2023-05-08 |
| 2021-12-31 | $986.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-08 | $986.00K derived: sum of 2 quarters · filed 2023-02-08 | -$8.62M derived: sum of 3 quarters · filed 2023-02-08 | -$264.00K 10-K · filed 2023-02-08 |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | -$9.61M derived: sum of 2 quarters · filed 2022-11-08 | -$1.25M 10-Q · filed 2022-11-08 | $0.00 derived: sum of 4 quarters · filed 2023-02-08 |
| 2021-06-30 | -$9.61M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-08 | -$1.25M 10-Q · filed 2022-08-08 | $0.00 derived: sum of 3 quarters · filed 2023-02-08 | $0.00 derived: sum of 4 quarters · filed 2023-02-08 |
| 2021-03-31 | $8.36M 10-Q · filed 2022-05-05 | $9.61M derived: sum of 2 quarters · filed 2023-02-08 | $9.61M derived: sum of 3 quarters · filed 2023-02-08 | $9.61M derived: sum of 4 quarters · filed 2023-02-08 |
| 2020-12-31 | $1.25M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-08 | $1.25M derived: sum of 2 quarters · filed 2023-02-08 | $1.25M derived: sum of 3 quarters · filed 2023-02-08 | $1.25M 10-K · filed 2023-02-08 |
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-04 | $0.00 derived: sum of 2 quarters · filed 2021-11-04 | $0.00 10-Q · filed 2021-11-04 | |
| 2020-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-09 | $0.00 10-Q · filed 2021-08-09 | ||
| 2020-03-31 | $0.00 10-Q · filed 2021-05-04 | |||
| 2019-12-31 | $0.00 10-K · filed 2022-02-28 | |||
| 2018-12-31 | $0.00 10-K · filed 2021-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Pelthos Therapeutics Inc. (PTHS) | United States | $0.086B | -1.20 |
| COGNITION THERAPEUTICS INC (CGTX) | United States | $0.090B | -6.52 |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |
| Kalaris Therapeutics, Inc. (KLRS) | United States | $0.073B | -2.19 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |
| CHAMPIONS ONCOLOGY, INC. (CSBR) | United States | $0.070B | -68.02 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |